CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash Flows from Operating Activities:
Net loss	$ (85)	$ (16,114)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	19,036	5,846
Change in fair value of contingent consideration	(4,661)	285
Change in fair value of warrant liabilities	(27,162)	0
Loss on extinguishment of debt	1,428	0
Amortization of debt issuance costs	748	2,170
Non-cash lease expense	1,705	0
Stock-based compensation	13,816	71
Changes in operating assets and liabilities:
Accounts receivable, net	(58,291)	(6,929)
Other assets	(3,060)	(882)
Prepaid expenses and other current assets	1,773	(6,537)
Interest accrued due to sellers	97	536
Accounts payable and accrued expenses (Related parties comprised $0 and $421 for the years ended March 31, 2022 and 2021, respectively)	10,010	5,973
Other liabilities (Related parties comprised $0 and $1,073 for the years ended March 31, 2022 and 2021, respectively)	7,443	893
Net cash used in operating activities	(37,203)	(14,688)
Cash Flows from Investing Activities:
Purchase of property and equipment (Related parties comprised $1,677 and $1,073 for the years ended March 31, 2022 and 2021, respectively)	(7,776)	(2,645)
Acquisitions of subsidiaries including non-compete intangibles, net of cash acquired	(3,495)	(898)
Payments to sellers	(2,186)	(6,155)
Other	0	(1)
Net cash used in investing activities	(13,457)	(9,699)
Cash Flows from Financing Activities:
Capitalized transaction costs related to merger	0	(2,414)
Payments of long-term debt	(1,611)	(1,200)
Debt issuance costs	(87)	0
Proceeds from insurance financing arrangements	2,529	1,702
Payments of principal on insurance financing arrangements	(690)	(567)
Repayments of equipment loans	(129)	(76)
Repayments of capital lease obligations	(340)	(263)
Employee stock purchase plan contributions	870	0
Net cash provided by (used in) financing activities	542	(2,818)
Net decrease in cash, cash equivalents and restricted cash	(50,118)	(27,205)
Cash, cash equivalents and restricted cash at beginning of year	163,170	33,807
Cash, cash equivalents and restricted cash at end of period	113,052	6,602
Supplemental cash flow information:
Interest paid	4,525	8,260
Income taxes paid	8	0
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange of lease liabilities	26,364	651
Issuance of class A common stock for acquisitions	15,771	0
Due to sellers in connection with acquisitions	100	0
Addition to construction in process funded through accounts payable	2,972	0
Humana Affiliate Provider clinic leasehold improvements	2,173	1,073
ESPP issuance	$ 9,707	$ 0